Cognitive function in the early phase of Parkinson's disease, a five-year follow-up
M E Domellöf1, U Ekman1,2,3, L Forsgren1
1Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Background:
Presence of mild cognitive impairment (MCI) as a predictor for Parkinson's disease dementia (PDD) has been discussed from a clinical perspective. Recently, a Movement Disorder Society (MDS) commissioned Task Force published guidelines for PD-MCI. However, long-term follow-ups of the PD-MCI guidelines for the prediction of PDD have been sparse.
Method:
In a community-based cohort of PD, the MDS guidelines for PD-MCI and consensus criteria for PDD were applied on 147 subjects. The predictive ability of PD-MCI for PDD was investigated. Additionally, baseline comparisons were conducted between MCI that converted to PDD and those who did not, and evolvement of motor function was investigated.
Results:
One fourth of the population developed PDD. MCI and age at baseline predicted later occurrence of PDD, and baseline results of tests measuring episodic memory, visuospatial function, semantic fluency, and mental flexibility differed between MCI converters and non-converters. Postural instability/gait (PIGD) phenotype and education did not predict later occurrence of PDD, but increased postural/gait disturbances were shown across time in those developing dementia.
Conclusion:
The new PD-MCI guidelines are useful to detect patients at risk for developing PDD. The PIGD phenotype at diagnosis was not a predictor of PDD within 5 years, but the study supports a temporal association between postural/gait disturbances and PDD. Older patients with PD-MCI at baseline with decline in episodic memory, semantic fluency, and mental flexibility need to be carefully monitored regarding cognition and likely also for fall risk.
Insights
Mild cognitive impairment (MCI) predicts Parkinson's disease dementia (PDD). Older patients with MCI and cognitive decline require monitoring for PDD and fall risk.
Area of Science:
- Neurology
- Neuroscience
- Geriatrics
Background:
- Mild cognitive impairment (MCI) is a known predictor for Parkinson's disease dementia (PDD).
- Recent Movement Disorder Society (MDS) guidelines address PD-MCI, but long-term predictive data for PDD remain limited.
- Understanding PD-MCI progression is crucial for early PDD detection and management.
Purpose of the Study:
- To evaluate the predictive value of the MDS PD-MCI guidelines for the development of PDD.
- To identify baseline characteristics differentiating MCI converters to PDD from non-converters.
- To examine the evolution of motor function in relation to PDD development.
Main Methods:
- A community-based cohort of 147 Parkinson's disease (PD) patients was assessed using MDS PD-MCI and PDD criteria.
- Predictive ability of PD-MCI for PDD was investigated.
- Baseline cognitive and motor functions were compared between MCI converters and non-converters.
Main Results:
- One-fourth of the cohort developed PDD.
- MCI and older age at baseline predicted PDD development.
- Episodic memory, visuospatial function, semantic fluency, and mental flexibility deficits distinguished MCI converters.
- Postural instability/gait difficulty (PIGD) phenotype and education did not predict PDD, but gait disturbances worsened in those developing dementia.
Conclusions:
- The MDS PD-MCI guidelines effectively identify patients at risk for PDD.
- While PIGD was not an early predictor, gait disturbances show a temporal link with PDD.
- Older PD patients with MCI and specific cognitive declines warrant close monitoring for cognitive changes and fall risk.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neural Regulation
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...


